Literature DB >> 2845645

Nucleotide sequence of UK bovine rotavirus segment 4: possible host restriction of VP3 genes.

P Kantharidis1, M L Dyall-Smith, G W Tregear, I H Holmes.   

Abstract

The bovine UK and simian SA11 rotaviruses are commonly used VP7-type reference strains. Since the surface protein VP3 is a significant neutralization antigen, it is important to fully characterize the VP3 types associated with current reference strains. Here we present the complete nucleotide and predicted amino acid sequence of VP3 from UK rotavirus (VP7 type 6) and compare it to the published sequences of SA114fm and RV-5. We also compare the deduced amino acid sequence covering the trypsin cleavage region of UK VP3 to 25 other available sequences. The UK protein is clearly different from that of bovine NCDV (another commonly used VP7 type 6 strain) and represents a second VP3 type associated with bovine rotaviruses. Our SA11 sequence differs from that determined by Lopez et al. [1985, Virology 144, 11-19; later referred to as SA114fM by Lopez et al. (1986, Virology 154, 224-227], their sequence being very similar to the published sequence of NCDV VP3. The significance of these results with regard to virus serotypes is discussed. Finally, in analyzing the nucleotide sequence surrounding the initiation codon, a potential hairpin-loop structure was identified which may be involved in translational regulation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845645     DOI: 10.1016/0042-6822(88)90501-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Development of cDNA probes for typing group A bovine rotaviruses on the basis of VP4 specificity.

Authors:  A V Parwani; B I Rosen; M A McCrae; L J Saif
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

2.  Rotavirus YM gene 4: analysis of its deduced amino acid sequence and prediction of the secondary structure of the VP4 protein.

Authors:  S López; I López; P Romero; E Méndez; X Soberón; C F Arias
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals.

Authors:  D R Snodgrass; T A Fitzgerald; I Campbell; G F Browning; F M Scott; Y Hoshino; R C Davies
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

4.  Genome heterogeneity of SA11 rotavirus due to reassortment with "O" agent.

Authors:  Catie Small; Mario Barro; Thomas L Brown; John T Patton
Journal:  Virology       Date:  2006-10-23       Impact factor: 3.616

5.  Nucleotide sequence and expression in E. coli of the complete P4 type VP4 from a G2 serotype human rotavirus.

Authors:  N P Mahajan; C D Rao
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Nucleotide sequence of VP4 and VP7 genes of human rotaviruses with subgroup I specificity and long RNA pattern: implication for new G serotype specificity.

Authors:  K Taniguchi; T Urasawa; N Kobayashi; M Gorziglia; S Urasawa
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

7.  Presence of three P types (VP4 serotypes) and two G types (VP7 serotypes) among bovine rotavirus strains.

Authors:  Y Matsuda; O Nakagomi; P A Offit
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

8.  Reactivity of VP4-specific monoclonal antibodies to a serotype 4 porcine rotavirus with distinct serotypes of human (symptomatic and asymptomatic) and animal rotaviruses.

Authors:  S Y Kang; L J Saif; K L Miller
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

9.  Specificity and affinity of sialic acid binding by the rhesus rotavirus VP8* core.

Authors:  Philip R Dormitzer; Zhen-Yu J Sun; Ola Blixt; James C Paulson; Gerhard Wagner; Stephen C Harrison
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Bovine rotavirus type detection by neutralizing monoclonal antibodies.

Authors:  E Cornaglia; Y Elazhary; B Talbot
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.